Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Last trade$27.84
Day change-$0.705 (-2.47%)
Day range$27.16 – $28.72
Volume97,966
Market cap$1.45B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NBTX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NBTX.
Recent news
Company coverage with links to the original publishers.
NANOBIOTIX reported Phase 1 results for JNJ-1900 (NBTXR3), a nanoparticle-based therapy combined with immunotherapy, in 24 heavily pretreated patients with anti-PD-1 resistant melanoma. The study showed an objective response rate of 41.7%, disease control rate of 75%, and median overall survival of 17.8 months, with an acceptable safety profile. Exploratory analysis identified IL-1β as a key immune marker, supporting further evaluation in randomized trials.
NANOBIOTIX reported Phase 1 data for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 heavily pre-treated patients with anti-PD-1-resistant melanoma. The study showed a 41.7% overall response rate, 75% disease control rate, and 17.8 months median overall survival, with an acceptable safety profile. Exploratory analysis identified IL-1β as a key cytokine linked to treatment-induced anti-tumor immunity, warranting further evaluation in randomized clinical trials.
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
NANOBIOTIX completed a global offering raising approximately $100 million in gross proceeds through the full exercise of the underwriters' over-allotment option. The offering included 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. The company plans to allocate proceeds toward JNJ-1900 development (less than 10%), Nanoprimer and other platforms (50-60%), and general corporate needs (30-40%), with sufficient runway through 2029.
Nanobiotix, a late-clinical stage biotechnology company, announced the closing of its global offering on May 26, 2026, raising approximately $100 million in gross proceeds following the full exercise of underwriters' over-allotment option. The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. Net proceeds will be allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The company expects its financial resources to support operations into 2029.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.